Close Menu

siRNA

The deal represents an expansion of an ongoing partnership between Cenix and Janssen focused on improving in vivo siRNA-based target validation methodologies in the central nervous system.

The companies expect Precision's technology to enable RNAi drug delivery to tissues beyond the liver. The deal is the latest in a number of delivery agreements that have been struck in the last year.

Reconstituted HDL nanoparticles were loaded with siRNAs against two key cancer genes and administered intravenously into orthotopic mouse models of cancer, and were able to effectively silence the expression of their targets.

Cenix Joins EU siRNA Consortium

Premium

Cenix jumped on board after one-time member Novosom dropped out following the sale of its liposome-based delivery technology to Marina Biotech last year.

The presentation will focus on data from an ongoing phase I study with Atu027 in subjects with advanced solid cancer. “Key findings presented will include safety, tolerability and pharmacokinetic data, as well as indications of anti-tumor activity,” Silence said.

The study identified 27 genes that might impact colon cancer patients' response to oxaliplatin, a finding that could help Genomic Health add a treatment benefit indication to its Oncotype DX test.

The company said it will use the funds to advance new siRNA delivery compounds and add 10 new researchers and lab technicians.

The company plans to use the funding to enhance its R&D resources and to hire new researchers and lab technicians.

The phase I drug, ALN-VSP02, comprises two siRNAs, one targeting vascular endothelial growth factor and one targeting kinesin spindle protein, both of which the firm said are critical for the growth and survival of cancer cells.

The drug, STP705, uses a polymeric nanoparticle to enhance topical delivery of siRNAs targeting the TGF-beta 1 and Cox-2 genes to open wounds, Sirnaomics said.

Pages

Public health experts call for a transparent COVID-19 vaccine approval process in a letter; the Food and Drug Administration commissioner assures science-based approval.

The Verge reports that new gene-naming guidelines aim in part to avoid Excel-related name change confusion.

In Nature this week: tuatara genome sequence aids in understanding amniote evolution, and more.

According to the Guardian, UK virologists say in a letter to officials that their expertise has been pushed aside in COVID-19 response plans.